Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.715    0.025 (1.48%)
Bid:
1.50
Ask:
1.93
Spread: 0.43 (28.667%)
Market Cap: £5.93m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Directorate Change

1 Jul 2014 07:00

RNS Number : 9952K
Proteome Sciences PLC
01 July 2014
Β 

ο»Ώ

Β 

Β 

Β 

Β 

Β 

PRESS RELEASE

Β 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of Roger McDowell as Non-Executive Director

Β 

1st July, 2014 Proteome Sciences is pleased to announce the appointment of Roger Steven McDowell to the Board of the Company as a non-executive Director with immediate effect.

Β 

Roger McDowell has a highly successful career as a businessman and entrepreneur. He was Managing Director of Oliver Ashworth for eighteen years before its sale to St. Gobain. He is currently the Chairman or a non-executive director of seven listed companies, namely Avingtrans plc, Servelec Group plc, Renovo plc, Alkane Energy plc, Swallowfield plc, IS Solutions plc and Augean plc. He brings considerable commercial experience with him and is a keen exponent of growing shareholder value.

Β 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Roger Steven McDowell, age 60 years, is or has been a director of the following companies during the five years preceding the date of this announcement:

Β 

Current directorships Past directorships

Corsair Techinvest Ltd One Advice Group plc

Fineguard Ltd Ultimate Finance Group plc

Augean plc

Disperse Ltd

Dovehoco 201 Ltd

Avingtrans plc

IS Solutions plc

Swallowfield plc

Alkane Energy plc

Renovo plc

Servelec Group plc

Β 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.Β 

Β 

At the AGM, held on 30 June 2014, it was announced that Steve Harris, the Chairman, was proposing to retire and he has now formally stepped down as a director.

Β 

The Board of Proteome Sciences would like to thank him for the considerable contribution and support that he has provided to the Company over the last 20 years, a period in which the Company's outstanding biomarker research has been converted into products, services and commercial revenue. We wish him a long and enjoyable retirement.

Β 

The CEO, Christopher Pearce, has been appointed Executive Chairman. Dr. Ian Pike remains the Chief Operating Officer.

Β 

Β 

- Ends -

Β 

Β 

Β 

Β 

Β 

Β 

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Tel: +44 (0)1932 865065

Dr. Ian Pike, Chief Operating Officer

James Malthouse, Finance Director

Nominated Adviser

Cenkos

Stephen Keys/Callum Davidson

Tel: +44 (0)20 7397 8900

Public Relations

IKON Associates

Adrian Shaw

Tel: +44 (0)1483 271291

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BOAKBLFXZQFEBBD
Date   Source Headline
14th Aug 201810:03 amRNSDirector/PDMR Shareholding
9th Aug 20181:23 pmRNSDirector/PDMR Shareholding
2nd Aug 201810:03 amRNSDirector/PDMR Shareholding
31st Jul 20184:09 pmRNSDirector/PDMR Shareholding
27th Jul 201812:21 pmRNSDirector/PDMR Shareholding
24th Jul 20187:00 amRNSInterim Results
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
3rd Jul 20187:00 amRNSLoan Agreement and Notice of Results
18th Jun 20184:40 pmRNSSecond Price Monitoring Extn
18th Jun 20184:35 pmRNSPrice Monitoring Extension
30th May 20181:36 pmRNSAGM Statement
24th Apr 20187:00 amRNSBoard Appointment
24th Apr 20187:00 amRNSPreliminary Results
3rd Apr 201810:40 amRNSBlock Admission return
3rd Apr 20187:00 amRNSLicense Agreement Extension
28th Mar 20187:00 amRNSNotice of Results
22nd Mar 20181:18 pmRNSDirector/PDMR Shareholding
15th Mar 20184:40 pmRNSSecond Price Monitoring Extn
15th Mar 20184:35 pmRNSPrice Monitoring Extension
12th Feb 20187:00 amRNSTrading Update
10th Nov 201710:11 amRNSHolding(s) in Company
8th Nov 201712:00 pmRNSDirector/PDMR Shareholding
27th Oct 201711:30 amRNSHolding(s) in Company
27th Oct 201711:30 amRNSDirector/PDMR Shareholding
23rd Oct 201712:00 pmRNSHolding(s) in Company
23rd Oct 201712:00 pmRNSDirector/PDMR Shareholding
20th Oct 201712:58 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSGCLP Accreditation and Trading Update
3rd Oct 20172:25 pmRNSBlock Admission Return
1st Sep 201712:08 pmRNSIssue of Equity
1st Aug 20177:00 amRNSDirectorate Changes
25th Jul 20177:00 amRNSInterim results for the 6 months to 30 June 2017
11th Jul 201712:00 pmRNSNotice of Results
30th Jun 201710:31 amRNSHolding(s) in Company
30th Jun 20177:00 amRNSStroke Diagnostic- Research Milestone Achieved
12th Jun 20177:00 amRNSNew Registered Address
8th Jun 20174:40 pmRNSSecond Price Monitoring Extn
8th Jun 20174:35 pmRNSPrice Monitoring Extension
15th May 20177:00 amRNSDirector/PDMR Shareholding
10th May 201710:09 amRNSDirector/PDMR Shareholding
5th May 201712:30 pmRNSDirector/PDMR Shareholding
4th May 20172:23 pmRNSHolding(s) in Company
3rd May 20177:00 amRNSDirector/PDMR Shareholding
28th Apr 20174:58 pmRNSDirector/PDMR Shareholding
28th Apr 20174:54 pmRNSHolding(s) in Company
25th Apr 20171:34 pmRNSAGM Statement and Result of AGM
11th Apr 20177:00 amRNSDirector Dealing and Total Voting Rights
4th Apr 20175:00 pmRNSHolding(s) in Company
4th Apr 20174:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.